Oppenheimer Upgrades Incyte to Outperform Amid Growth Potential Beyond Jakafi
Oppenheimer has upgraded Incyte (INCY) from 'Market Perform' to 'Outperform,' signaling confidence in the biotechnology company's long-term growth trajectory. The upgrade is driven by expectations that Incyte can successfully expand its revenue streams beyond its flagship product, Jakafi (ruxolitinib), which faces loss of exclusivity in 2029. Analyst George Clerk set a price target of $144 for the stock, representing approximately 23% upside from its October 29 closing price. The move suggests that investors should look toward Incyte's broader pipeline and diversification strategies as key drivers for future valuation.
Tickers: $INCY